Comparison of Three Cardiovascular Risk Scores among HIV-Infected Patients in Korea: The Korea HIV/AIDS Cohort Study

다국어 초록 (Multilingual Abstract)

Background We investigated cardiovascular disease (CVD), risk factors for CVD, and applicability of the three known CVD risk equations in the Korean human immunodeficiency virus/ Acquired Immune Deficiency Syndrome (HIV/AIDS) cohort.




Materials and Methods The study parcitipants were HIV-infected patients in a Korean HIV/AIDS cohort enrolled from 19 hospitals between 2006 and 2017. Data collected at entry to the cohort were analyzed. The 5-year CVD risk in each participant was calculated using three CVD risk equations: reduced CVD prediction model of HIV-specific data collection on adverse effects of anti-HIV drugs (R-DAD), Framingham general CVD risk score (FRS), and Korean Coronary Heart Disease Risk Score (KRS).




Results CVD events were observed in 11 of 586 HIV-infected patients during a 5-year (median) follow-up period. The incidence of CVD was 4.11 per 1,000 person-years. Older age (64 vs. 41 years, P = 0.005) and diabetes mellitus (45.5% vs. 6.4%, P <0.001) were more frequent in patients with CVD. Using R-DAD, FRS, and KRS, 1.9%, 2.4%, and 0.7% of patients, respectively, were considered to have a very high risk (≥10%) of 5-year CVD. The discriminatory capacities of the three prediction models were good, with c-statistic values of 0.829 (P <0.001) for R-DAD, 0.824 (P <0.001) for FRS, and 0.850 (P = 0.001) for KRS.




Conclusion The FRS, R-DAD, and KRS performed well in the Korean HIV/AIDS cohort. A larger cohort and a longer period of follow-up may be necessary to demonstrate the risk factors and develop an independent CVD risk prediction model specific to Korean patients with HIV.

다국어 초록 (Multilingual Abstract)

Background We investigated cardiovascular disease (CVD), risk factors for CVD, and applicability of the three known CVD risk equations in the Korean human immunodeficiency virus/ Acquired Immune Deficiency Syndrome (HIV/AIDS) cohort.


Materials and Methods The study parcitipants were HIV-infected patients in a Korean HIV/AIDS cohort enrolled from 19 hospitals between 2006 and 2017. Data collected at entry to the cohort were analyzed. The 5-year CVD risk in each participant was calculated using three CVD risk equations: reduced CVD prediction model of HIV-specific data collection on adverse effects of anti-HIV drugs (R-DAD), Framingham general CVD risk score (FRS), and Korean Coronary Heart Disease Risk Score (KRS).


Results CVD events were observed in 11 of 586 HIV-infected patients during a 5-year (median) follow-up period. The incidence of CVD was 4.11 per 1,000 person-years. Older age (64 vs. 41 years, P = 0.005) and diabetes mellitus (45.5% vs. 6.4%, P <0.001) were more frequent in patients with CVD. Using R-DAD, FRS, and KRS, 1.9%, 2.4%, and 0.7% of patients, respectively, were considered to have a very high risk (≥10%) of 5-year CVD. The discriminatory capacities of the three prediction models were good, with c-statistic values of 0.829 (P <0.001) for R-DAD, 0.824 (P <0.001) for FRS, and 0.850 (P = 0.001) for KRS.


Conclusion The FRS, R-DAD, and KRS performed well in the Korean HIV/AIDS cohort. A larger cohort and a longer period of follow-up may be necessary to demonstrate the risk factors and develop an independent CVD risk prediction model specific to Korean patients with HIV.

참고문헌 (Reference)

1 D:A:D Study Group, "Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D : A : D study : a multi-cohort collaboration" 371 : 1417-1426, 2008

2 Nordell AD, "Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation" 3 : e000844-, 2014

3 French MA, "Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells" 200 : 1212-1215, 2009

4 Hsue PY, "Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis" 23 : 1059-1067, 2009

5 Liu J, "Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study" 291 : 2591-2599, 2004

6 Friis-Møller N, "Predicting the risk of cardiovascular disease in HIV-infected patients : the data collection on adverse effects of anti-HIV drugs study" 17 : 491-501, 2010

7 Hasse B, "Morbidity and aging in HIV-infected persons : the Swiss HIV cohort study" 53 : 1130-1139, 2011

8 McManus H, "Long-term survival in HIV positive patients with up to 15Years of antiretroviral therapy" 7 : e48839-, 2012

9 Dhillon S, "Level of agreement between frequently used cardiovascular risk calculators in people living with HIV" 20 : 347-352, 2019

10 최보율 ; 최준용 ; 한상훈 ; 김상일 ; 기미경 ; 김민자 ; 김신우 ; 김성순 ; 김유미 ; 구남수 ; 이진수 ; 이주실 ; 최윤수 ; 박경실 ; 송준영 ; 우준희 ; 강문원 ; 김준명, "Korea HIV/AIDS Cohort Study: study design and baseline characteristics" 한국역학회 40 : 1-8, 2018

11 Phillips AN, "Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection : exploratory analyses from the SMART trial" 13 : 177-187, 2008

12 Kuller LH, "Inflammatory and coagulation biomarkers and mortality in patients with HIV infection" 5 : e203-, 2008

13 Freiberg MS, "HIV infection and the risk of acute myocardial infarction" 173 : 614-622, 2013

14 Yusuf S, "Global burden of cardiovascular diseases : Part II : variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies" 104 : 2855-2864, 2001

15 D’Agostino RB Sr, "General cardiovascular risk profile for use in primary care : the Framingham Heart Study" 117 : 743-753, 2008

16 DAD Study Group, "Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction" 356 : 1723-1735, 2007

17 Ahn KA, "Framingham equation model overestimates risk of ischemic heart disease in Korean men and women" 28 : 162-170, 2006

18 Rabanal KS, "Ethnic inequalities in acute myocardial infarction and stroke rates in Norway 1994-2009 : a nationwide cohort study(CVDNOR)" 15 : 1073-, 2015

19 Rabanal KS, "Ethnic differences in risk factors and total risk of cardiovascular disease based on the Norwegian CONOR study" 20 : 1013-1021, 2013

20 최윤수 ; 최보율 ; Soo Min Kim ; Sang-Il Kim ; June Kim ; Jun Young Choi ; Shin Woo Kim ; Joon Young Song ; Youn Jeong Kim ; Dae Won Park ; Hyo Youl Kim ; 최희정 ; Mee-Kyung Kee ; YoungHyun Shin ; Myeongsu Yoo, "Epidemiological characteristics of HIV infected Korean: Korea HIV/AIDS Cohort Study" 한국역학회 41 : 1-9, 2019

21 Rotger M, "Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons" 57 : 112-121, 2013

22 Begovac J, "Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy" 56 : 14-23, 2015

23 Triant VA, "Cardiovascular risk prediction functions underestimate risk in HIV infection" 137 : 2203-2214, 2018

24 Policarpo S, "Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms" 38 : 463-470, 2019

25 Pirš M, "Cardiovascular risk assessment in HIVinfected male patients : a comparison of Framingham, SCORE, PROCAM and DAD risk equations" 23 : 43-47, 2014

26 Nery MW, "Cardiovascular risk assessment : a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons" 2013 : 969281-, 2013

27 Anderson KM, "Cardiovascular disease risk profiles" 121 : 293-298, 1991

28 Strategies for Management of Antiretroviral Therapy (SMART) Study Group, "CD4+ count-guided interruption of antiretroviral treatment" 355 : 2283-2296, 2006

29 Ryom L, "Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function : the D : A : D study" 207 : 1359-1369, 2013

30 Noumegni SR, "Assessment of the agreement between the Framingham and DAD risk equations for estimating cardiovascular risk in adult Africans living with HIV infection : a cross-sectional study" 3 : 12-, 2017

31 Mashinya F, "Assessment of cardiovascular risk factors in people with HIV infection treated with ART in rural South Africa : a cross sectional study" 12 : 42-, 2015

32 Friis-Møller N, "An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons : The data-collection on adverse effects of anti-HIV drugs(D : A : D)study" 23 : 214-223, 2016

33 Jee SH, "A coronary heart disease prediction model : the Korean Heart Study" 4 : e005025-, 2014

34 Kim SB, "A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea" 45 : 855-862, 2013